Corporate Responsibility performance summary 2014/15

Our Organisation

With 14,874 employees in more than 30 countries, CSL recorded another strong year of performance generating revenues of US$5.6 billion. On 3 August 2015, CSL announced the successful acquisition of Novartis’ global influenza vaccine business. The integration of bioCSL with Novartis’ influenza vaccine operations# has resulted in the formation of Seqirus – the world’s second largest influenza vaccine business.

Researching new medicines

CSL achieved 14 product registrations or new indications for serious diseases. We made significant progress on the development of a family of novel recombinant coagulation factor medicines for the treatment of haemophilia A and B. Dossiers for our products have been submitted to regulators, with phase III data for our long-acting recombinant coagulation factor IX (rIX-FP) indicating rIX-FP has the potential to be a best-in-class therapy for adults and children with haemophilia B. In addition, we progressed a potential new breakthrough medicine, with a Phase IIb global study investigating multiple dose administration of CSL112 in 1,200 patients who have experienced an acute myocardial infarction or heart attack.

Ensuring the quality and safety of our therapies

CSL’s key manufacturing facilities and plasma collection centres were audited 263 times with no alterations to our product marketing licences. Our vigilance to patient safety resulted in three product recalls with 497 quality audits of supplies conducted. CSL’s newly established Global Counterfeit Task Force worked closely with authorities to respond to instances of counterfeit product in three countries. We successfully responded to regulatory outcomes of our pharmacovigilance system and continued efforts to align and harmonise quality management systems and processes across our operations.

Operating responsibly in the marketplace

CSL distributed US$5 billion to employees, suppliers, shareholders and governments, a slight increase on the previous year. In Australia we actively participated in government inquiries focussed on Australia’s innovation system, tax reform and the economic benefits of research. In the US and Europe we continued our public policy efforts to support the protection and access to therapies for rare and serious diseases. During the reporting year 98% of employees undertook training in our Code of Responsible Business Practice and 82% of eligible employees completed anti-bribery and anti-corruption training. Over the reporting period, no breaches were found by the regulators for our product marketing and promotional activities.

Providing a positive working environment for our people

Following two consecutive years of 7% growth per annum, CSL’s workforce increased by 10%, largely due to our expanding CSL Plasma footprint. Of total employees, women continue to represent the majority of the workforce at 57%. In addition, women accounted for 42% of the ‘manager and above’ workforce, steady with the prior year, and 31% of CSL’s most senior positions, at vice president and above levels, a slight increase. CSL’s recorded rates of lost time injury frequency (LTIFR), days lost frequency (DLFR) and serious injury/illness frequency (SIIFR) decreased by 47%, 37% and 54% respectively, while the medical treatment incident frequency rate (MTIFR) increased by 8%.

Supporting our communities around the world

CSL contributed US$28.4 million towards global community efforts, a reduction on the previous year largely due to bioCSL’s once-off donation of 763,000 doses of influenza vaccine in 2013/14 to Laos. In April 2015, CSL announced it will provide 10 million international units (IUs) of one or more of our broad portfolio of bleeding disorder protein therapy products to the World Federation of Hemophilia (WFH) over a three year period commencing in 2016. Along with CSL Behring’s longstanding Professor Heimburger Awards and The Interlaken Leadership Award, in November 2014, Professor Carola Vinuesa was awarded the inaugural 2014 CSL Young Florey Medal for outstanding early career biomedical research. In Nepal, where there was significant loss of life due to a natural disaster, CSL Behring, through the WFH, donated 216,000 IUs of human coagulation factor IX to help patients with bleeding disorders.

Minimising our environmental impacts

CSL maintained compliance with all applicable environmental laws and regulations. With an increasing facility footprint, our environmental intensities and absolute numbers for energy and water consumption, and greenhouse gas emissions, increased modestly, however the rate at which waste is recycled improved. CSL’s manufacturing site in Marburg, Germany, achieved ISO 50001 certification for Energy Management. In 2015, following an enterprise-wide climate change risk assessment, CSL concluded it is not exposed to climate change risks that have a potential to generate a substantive change in our business operations, revenue or expenditure in the next 25 years.




View our Performance Data Summary.



# Unless stated, data provided in this report does not include the Novartis influenza vaccine business.